Dyne Therapeutics (DYN)
NASDAQ:DYN
DYN Stock Chart & Stats
$18.68
-$0.74(-3.10%)
At close: 4:00 PM EST
$18.68
-$0.74(-3.10%)
Day’s Range― - ―
52-Week Range$7.01 - $25.00
Previous CloseN/A
Volume117.44K
Average Volume (3M)2.32M
Market Cap
$3.08B
Enterprise Value$2.21B
Total Cash (Recent Filing)$1.11B
Total Debt (Recent Filing)$20.28M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Apr 30, 2026EPS Estimate
-0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.76
Shares Outstanding165,027,110
10 Day Avg. Volume1,444,441
30 Day Avg. Volume2,315,597
Financial Highlights & Ratios
PEG Ratio-1.90
Price to Book (P/B)2.58
Price to Sales (P/S)0.00
P/FCF Ratio-6.20
Enterprise Value/Market Cap0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.24K
Enterprise Value/Ebitda-5.05
Forecast
1Y Price Target
$39.57Price Target Upside111.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.16
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Multisystem Clinical BenefitReported improvements in heart and lung function alongside sustained increases in target protein suggest the therapy could deliver broad, disease‑modifying benefits across multiple affected tissues.
Regulatory DesignAgreement with regulators on a confirmatory late‑stage trial using a timed sit‑to‑stand functional measure improves the chance that study results will be considered clinically meaningful by authorities and clinicians.
Safety And Patient AdoptionA favorable safety and tolerability profile combined with less frequent dosing than the current standard could support patient uptake and differentiate the product commercially.
Bears Say
Data RobustnessEarly efficacy signals were generated from very small patient groups, making the estimated treatment effect fragile and raising the risk that results may not hold in a larger, properly powered trial.
Funding RiskHigh annual cash burn and a limited cash runway increase the likelihood of financing pressure that could delay development milestones or lead to shareholder dilution before key approvals are achieved.
Reimbursement And Commercial RiskKey opinion leaders indicate that myotonia is not the primary burden for many patients, creating a risk that payers may not provide broad coverage if approval relies mainly on myotonia measures.
Dyne Therapeutics News
DYN FAQ
What was Dyne Therapeutics’s price range in the past 12 months?
Dyne Therapeutics lowest stock price was $7.01 and its highest was $25.00 in the past 12 months.
What is Dyne Therapeutics’s market cap?
Dyne Therapeutics’s market cap is $3.08B.
When is Dyne Therapeutics’s upcoming earnings report date?
Dyne Therapeutics’s upcoming earnings report date is Apr 30, 2026 which is in 17 days.
How were Dyne Therapeutics’s earnings last quarter?
Dyne Therapeutics released its earnings results on Mar 02, 2026. The company reported -$0.76 earnings per share for the quarter, beating the consensus estimate of -$0.763 by $0.003.
Is Dyne Therapeutics overvalued?
According to Wall Street analysts Dyne Therapeutics’s price is currently Undervalued.
Does Dyne Therapeutics pay dividends?
Dyne Therapeutics does not currently pay dividends.
What is Dyne Therapeutics’s EPS estimate?
Dyne Therapeutics’s EPS estimate is -0.77.
How many shares outstanding does Dyne Therapeutics have?
Dyne Therapeutics has 165,027,110 shares outstanding.
What happened to Dyne Therapeutics’s price movement after its last earnings report?
Dyne Therapeutics reported an EPS of -$0.76 in its last earnings report, beating expectations of -$0.763. Following the earnings report the stock price went up 3.393%.
Which hedge fund is a major shareholder of Dyne Therapeutics?
Currently, no hedge funds are holding shares in DYN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dyne Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.57 (111.83% Upside)
$39.57 (111.83% Upside)
Blogger Sentiment
Bullish
DYN Sentiment 80%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 4.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $118.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.3%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
167.62%
12-Months-Change
Fundamentals
Return on Equity
-61.45%
Trailing 12-Months
Asset Growth
71.72%
Trailing 12-Months
Company Description
Dyne Therapeutics
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
DYN Stock 12 Month Forecast
Average Price Target
$39.57
▲(111.83% Upside)
Technical Analysis
Sarepta Therapeutics
―
Cogent Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Immunocore Holdings
―
Ownership Overview
Currently, No data available
---